{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:20:34Z","timestamp":1783603234004,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020777","name":"Zhejiang Pharmaceutical Association","doi-asserted-by":"publisher","award":["2020ZYY15"],"award-info":[{"award-number":["2020ZYY15"]}],"id":[{"id":"10.13039\/501100020777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020777","name":"Zhejiang Pharmaceutical Association","doi-asserted-by":"publisher","award":["2022ZYYL05"],"award-info":[{"award-number":["2022ZYYL05"]}],"id":[{"id":"10.13039\/501100020777","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["No. ZCLQ24H0901"],"award-info":[{"award-number":["No. ZCLQ24H0901"]}]},{"name":"the research project on high quality development of Hospital pharmacy, National Institute of Hospital Administration, NHC, China","award":["No. NIHAYSZX2533"],"award-info":[{"award-number":["No. NIHAYSZX2533"]}]},{"name":"Project of Development Center for medical science and technology National Health Commission","award":["WKZX2024CX501205"],"award-info":[{"award-number":["WKZX2024CX501205"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50727-4","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T17:02:50Z","timestamp":1778432570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of clinical evaluation index system for first-line ICIs in HER-2-negative advanced gastric cancer using Delphi-AHP"],"prefix":"10.1038","volume":"16","author":[{"given":"Tiantian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Difei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"issue":"3","key":"50727_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"issue":"9742","key":"50727_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang, Y-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (9742), 687\u2013697 (2010).","journal-title":"Lancet"},{"issue":"1","key":"50727_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. Ca 75 (1), 10 (2025).","journal-title":"Ca"},{"issue":"10","key":"50727_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/CM9.0000000000002980","volume":"137","author":"N Dong","year":"2024","unstructured":"Dong, N. et al. Clinical application and management of temporary mechanical circulatory support: A clinical consensus. Chin. Med. J. 137 (10), 1135\u20131139 (2024).","journal-title":"Chin. Med. J."},{"issue":"7517","key":"50727_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"CGAR Network","year":"2014","unstructured":"Network, C. G. A. R. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (7517), 202 (2014).","journal-title":"Nature"},{"issue":"14","key":"50727_CR6","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-20-0075","volume":"26","author":"Y Kubota","year":"2020","unstructured":"Kubota, Y. et al. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clin. Cancer Res. 26 (14), 3784\u20133790 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"50727_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24 (11), 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"issue":"4","key":"50727_CR8","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s12325-024-03069-4","volume":"42","author":"S Qin","year":"2025","unstructured":"Qin, S. et al. First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study. Adv. Ther. 42 (4), 1892\u20131906 (2025).","journal-title":"Adv. Ther."},{"issue":"2","key":"50727_CR9","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","volume":"9","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. 9 (2), 102226 (2024).","journal-title":"ESMO Open."},{"issue":"5","key":"50727_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani, J. A. et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J. Natl. Compr. Canc Netw. 23 (5), 169\u2013191 (2025).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"50727_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH W","year":"2024","unstructured":"W, F. H., Z, X. T. & R.-B.Wang, C. L. H. Q. M. Z. .Zhou Z.-W.Zhou A.-P.Jin J.Yuan X.-L.Bi F.Liu T.-S.Liang H.Zhang Y.-Q.Li G.-X.Liang J.Liu B.-R.Shen L.Li J.Xu R.-H. TLWQCM-YLY-FQX-JQHZY-JYJ-EZJSL-YL. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 44 (1), 127\u2013172 (2024).","journal-title":"Cancer Commun."},{"issue":"17","key":"50727_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J. Clin. Oncol. 42 (17), 21 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"50727_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2169\/internalmedicine.5893-20","volume":"60","author":"Y Yatsuda","year":"2021","unstructured":"Yatsuda, Y. et al. A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. Intern. Med. 60 (7), 1011\u20131017 (2021).","journal-title":"Intern. Med."},{"issue":"5","key":"50727_CR14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.21873\/anticanres.17583","volume":"45","author":"Y Hojo","year":"2025","unstructured":"Hojo, Y. et al. Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer. Anticancer Res. 45 (5), 2091\u20132102 (2025).","journal-title":"Anticancer Res."},{"issue":"1","key":"50727_CR15","doi-asserted-by":"publisher","first-page":"30983","DOI":"10.1038\/s41598-024-82105-3","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors. Sci. Rep. 14 (1), 30983 (2024).","journal-title":"Sci. Rep."},{"key":"50727_CR16","doi-asserted-by":"crossref","unstructured":"Nayak, R. K. et al. Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy. J. Immunother. Cancer 12 (10). (2024).","DOI":"10.1136\/jitc-2024-010116"},{"issue":"1","key":"50727_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan, W. L., He, Y. & Xu, R. H. Gastric cancer treatment: recent progress and future perspectives. J. Hematol. Oncol. 16 (1), 57 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"50727_CR18","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Zhang, L., Fu, Y., Wang, M. & Zhang, L. Socioeconomic disparities in cancer treatment, service utilization and catastrophic health expenditure in China: a cross-sectional analysis. Int. J. Environ. Res. Public Health 17 (4). (2020).","DOI":"10.3390\/ijerph17041327"},{"issue":"2","key":"50727_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11096-023-01681-y","volume":"46","author":"ML Canning","year":"2024","unstructured":"Canning, M. L. et al. Defining quality indicators, pharmaceutical care bundles and outcomes of clinical pharmacy service delivery using a Delphi consensus approach. Int. J. Clin. Pharm. 46 (2), 451\u2013462 (2024).","journal-title":"Int. J. Clin. Pharm."},{"issue":"11","key":"50727_CR20","first-page":"14336","volume":"38","author":"A Ishizaka","year":"2011","unstructured":"Ishizaka, A. & Labib, A. Review of the main developments in the analytic hierarchy process. Expert Syst. Appl. 38 (11), 14336\u201314345 (2011).","journal-title":"Expert Syst. Appl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50727-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50727-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50727-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:02:52Z","timestamp":1783602172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50727-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50727"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50727-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21369"}}